Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HALO Halozyme Therapeutics	$52.21 -0.6%	$56.02	$42.01 ▼ $70.51	$6.43B	1.19	1.73 million shs	21.38 million shs
HQY HealthEquity	$104.88 +0.0%	$98.01	$65.01 ▼ $116.65	$9.07B	0.49	851,782 shs	958,705 shs
MPLN MultiPlan	$43.58 +1.9%	$30.14	$4.80 ▼ $29.84	$704.73M	0.13	117,045 shs	1.21 million shs
NUTX Nutex Health	$122.90 +3.7%	$136.17	$4.16 ▼ $184.28	$683.32M	0.03	82,902 shs	691,539 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HALO Halozyme Therapeutics	0.00%	-1.14%	-6.73%	-18.18%	-0.29%
HQY HealthEquity	0.00%	+3.53%	+3.73%	+18.68%	+21.67%
MPLN MultiPlan	0.00%	+8.95%	+63.47%	+109.82%	+4,357,999,900.00%
NUTX Nutex Health	0.00%	+7.91%	-27.15%	+161.32%	+1,965.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HALO Halozyme Therapeutics	4.7952 of 5 stars	3.1	1.0	4.4	2.1	2.5	4.4
HQY HealthEquity	3.6565 of 5 stars	3.5	3.0	0.0	2.7	2.5	1.9
MPLN MultiPlan	0.1849 of 5 stars	1.0	0.0	0.0	0.0	1.7	0.6
NUTX Nutex Health	3.3198 of 5 stars	3.5	2.0	0.0	2.6	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HALO Halozyme Therapeutics	2.17	Hold	$61.90	18.56% Upside
HQY HealthEquity	3.00	Buy	$118.09	12.60% Upside
MPLN MultiPlan	2.00	Hold	$26.25	-39.77% Downside
NUTX Nutex Health	3.00	Buy	$262.50	113.59% Upside

Current Analyst Ratings Breakdown

Latest HQY, MPLN, NUTX, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	HQY HealthEquity	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $125.00
6/5/2025	HQY HealthEquity	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$98.00 ➝ $115.00
6/4/2025	HQY HealthEquity	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$94.00 ➝ $104.00
6/4/2025	HQY HealthEquity	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $117.00
6/4/2025	HQY HealthEquity	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$110.00 ➝ $117.00
6/4/2025	HQY HealthEquity	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$110.00 ➝ $125.00
5/29/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
5/22/2025	HQY HealthEquity	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$105.00 ➝ $112.00
5/20/2025	NUTX Nutex Health	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $225.00
5/15/2025	NUTX Nutex Health	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$150.00 ➝ $300.00
5/14/2025	HALO Halozyme Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$73.00 ➝ $62.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HALO Halozyme Therapeutics	$1.02B	6.34	$4.65 per share	11.22	$2.86 per share	18.26
HQY HealthEquity	$1.20B	7.56	$4.26 per share	24.60	$24.40 per share	4.30
MPLN MultiPlan	$930.62M	0.76	$26.57 per share	1.64	$105.45 per share	0.41
NUTX Nutex Health	$479.95M	1.42	$13.17 per share	9.33	$37.13 per share	3.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HALO Halozyme Therapeutics	$444.09M	$3.76	13.89	8.39	0.35	44.76%	136.91%	26.05%	8/5/2025 (Estimated)
HQY HealthEquity	$96.70M	$1.37	76.55	36.93	1.61	9.80%	11.01%	6.77%	9/2/2025 (Estimated)
MPLN MultiPlan	-$91.70M	-$101.54	N/A	N/A	N/A	-163.30%	-12.14%	-1.84%	N/A
NUTX Nutex Health	$52.18M	$11.89	10.34	∞	N/A	10.76%	42.08%	11.80%	8/6/2025 (Estimated)

Latest HQY, MPLN, NUTX, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q1 2026	HQY HealthEquity	$0.81	$0.97	+$0.16	$0.61	$322.25 million	$330.80 million
5/13/2025	Q1 2025	NUTX Nutex Health	-$0.15	$2.56	+$2.71	$2.56	$81.09 million	$211.79 million
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million
3/31/2025	Q4 2024	NUTX Nutex Health	-$0.09	$11.12	+$11.21	$11.12	$81.13 million	$81.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
HQY HealthEquity	N/A	N/A	N/A	N/A	N/A
MPLN MultiPlan	N/A	N/A	N/A	N/A	N/A
NUTX Nutex Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HALO Halozyme Therapeutics	3.13	8.39	7.30
HQY HealthEquity	0.50	4.06	4.06
MPLN MultiPlan	21.73	1.05	1.05
NUTX Nutex Health	1.02	2.27	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HALO Halozyme Therapeutics	97.79%
HQY HealthEquity	99.55%
MPLN MultiPlan	87.15%
NUTX Nutex Health	5.32%

Insider Ownership

Company	Insider Ownership
HALO Halozyme Therapeutics	2.90%
HQY HealthEquity	1.50%
MPLN MultiPlan	8.00%
NUTX Nutex Health	36.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HALO Halozyme Therapeutics	390	123.22 million	119.65 million	Optionable
HQY HealthEquity	3,120	86.47 million	85.18 million	Optionable
MPLN MultiPlan	170	16.17 million	14.88 million	Optionable
NUTX Nutex Health	1,150	5.56 million	3.50 million	Not Optionable

HQY, MPLN, NUTX, and HALO Headlines

Recent News About These Companies

NUTEX HEALTH ANNOUNCES THAT IT HAS FILED A SUPPLEMENT TO ITS PROXY STATEMENT

June 27 at 6:30 AM | prnewswire.com

NUTEX HEALTH INC. ADDED TO RUSSELL 3000® INDEX AND RUSSELL MICROCAP® INDEX

June 24, 2025 | prnewswire.com

Nutex Health Leverages Arbitration To Unlock Hidden Value

June 19, 2025 | seekingalpha.com

Nutex Health (NASDAQ:NUTX) Trading Down 5% - Here's Why

June 17, 2025 | marketbeat.com

Nutex Health (NASDAQ:NUTX) Trading 5.9% Higher - What's Next?

June 12, 2025 | marketbeat.com

Millennium Management LLC Acquires Shares of 6,727 Nutex Health Inc. (NASDAQ:NUTX)

June 12, 2025 | marketbeat.com

Nutex Health (NASDAQ:NUTX) Shares Down 5.9% - Here's Why

June 10, 2025 | marketbeat.com

8,986 Shares in Nutex Health Inc. (NASDAQ:NUTX) Bought by Squarepoint Ops LLC

June 7, 2025 | marketbeat.com

Nutex Health (NASDAQ:NUTX) Sees Large Volume Increase - Here's What Happened

June 6, 2025 | marketbeat.com

Nutex Health (NASDAQ:NUTX) Trading Down 4.4% - Here's Why

June 3, 2025 | marketbeat.com

Northern Trust Corp Takes $200,000 Position in Nutex Health Inc. (NASDAQ:NUTX)

June 3, 2025 | marketbeat.com

NUTEX HEALTH ANNOUNCES INTERNET AVAILABILITY OF PROXY MATERIALS FOR ITS 2025 ANNUAL MEETING

June 2, 2025 | prnewswire.com

Short Interest in Nutex Health Inc. (NASDAQ:NUTX) Rises By 76.0%

June 1, 2025 | marketbeat.com

Nutex Health Inc.: High-Growth Healthcare Innovator With Strong Momentum

May 29, 2025 | seekingalpha.com

Nutex Health Inc.: High-Growth Healthcare Innovator With Strong Momentum

May 29, 2025 | seekingalpha.com

Nutex Health appoints Grant Thornton as new auditor

May 23, 2025 | uk.investing.com

NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF GRANT THORNTON LLP AS ITS INDEPENDENT AUDITOR

May 22, 2025 | prnewswire.com

Houston's Nutex plans first San Antonio hospital, eyes potential further expansion

May 19, 2025 | bizjournals.com

Shuttered health center finds new life in first 'micro' hospital in San Antonio

May 19, 2025 | msn.com

Nutex Health: The Stock Has Gotten Ahead Of Itself As Arbitration Revenue Normalizes

May 16, 2025 | seekingalpha.com

Nutex Health, Inc. (NASDAQ:NUTX) Q1 2025 Earnings Call Transcript

May 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HQY, MPLN, NUTX, and HALO Company Descriptions

Halozyme Therapeutics NASDAQ:HALO

$52.21 -0.32 (-0.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$52.96 +0.75 (+1.44%)

As of 04:54 AM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HealthEquity NASDAQ:HQY

$104.88 +0.02 (+0.02%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$101.57 -3.31 (-3.16%)

As of 04:03 AM Eastern

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

MultiPlan NYSE:MPLN

$43.58 +0.83 (+1.94%)

As of 06/27/2025

MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.

Nutex Health NASDAQ:NUTX

$122.90 +4.44 (+3.75%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$123.50 +0.60 (+0.49%)

As of 05:02 AM Eastern

Nutex Health Inc. operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment owns and owns and leases land and hospital building. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. It also provides operational and managerial services, including management, billing, collections, human resources and recruiting, legal, accounting, and marketing. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time